- Stocks
- Healthcare
- NASDAQ: HTBX

Price (delayed)

$7.2

Market cap

$181.82M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.31

Enterprise value

$152.28M

The EPS has soared by 65% YoY and by 20% from the previous quarter

The quick ratio has grown by 42% from the previous quarter

Heat Biologics's net income has decreased by 33% YoY and by 4.8% from the previous quarter

The revenue has contracted by 20% YoY and by 12% from the previous quarter

What are the main financial stats of HTBX

Market
Valuations
Earnings

Shares outstanding

25.25M

Market cap

$181.82M

Enterprise value

$152.28M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.33

Price to sales (P/S)

67.41

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

58.92

Revenue

$2.58M

EBIT

-$27.29M

EBITDA

-$26.83M

Free cash flow

-$21.76M

Per share
Balance sheet
Liquidity

EPS

-$1.31

Free cash flow per share

-$0.9

Book value per share

$5.4

Revenue per share

$0.11

TBVPS

$5.91

Total assets

$144.47M

Total liabilities

$8.01M

Debt

$1.76M

Equity

$137.3M

Working capital

$130.83M

Debt to equity

0.01

Current ratio

43.95

Quick ratio

43.43

Net debt/EBITDA

1.1

Margins
Efficiency
Dividend

EBITDA margin

-1,038%

Gross margin

100%

Net margin

-1,055.8%

Operating margin

-1,060.4%

Return on assets

-23.9%

Return on equity

-25.8%

Return on invested capital

-30.9%

Return on capital employed

-19.3%

Return on sales

-1,055.8%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Heat Biologics stock price performed over time

Intraday

2.13%

1 week

-5.76%

1 month

12.5%

1 year

30.67%

YTD

34.33%

QTD

-1.1%

How have Heat Biologics's revenue and profit performed over time

Revenue

$2.58M

Gross profit

$2.58M

Operating income

-$27.41M

Net income

-$27.29M

Gross margin

100%

Net margin

-1,055.8%

The company's operating margin has shrunk by 77% YoY and by 25% QoQ

The net margin has dropped by 67% year-on-year and by 19% since the previous quarter

The operating income has declined by 41% year-on-year and by 10% since the previous quarter

Heat Biologics's net income has decreased by 33% YoY and by 4.8% from the previous quarter

What is Heat Biologics's growth rate over time

What is Heat Biologics stock price valuation

P/E

N/A

P/B

1.33

P/S

67.41

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

58.92

The EPS has soared by 65% YoY and by 20% from the previous quarter

The P/B is 26% below the 5-year quarterly average of 1.8 and 5% below the last 4 quarters average of 1.4

Heat Biologics's equity has increased by 18% QoQ

HTBX's price to sales (P/S) is 152% more than its 5-year quarterly average of 26.8 and 69% more than its last 4 quarters average of 39.9

The revenue has contracted by 20% YoY and by 12% from the previous quarter

How efficient is Heat Biologics business performance

HTBX's return on invested capital has surged by 86% year-on-year and by 25% since the previous quarter

The company's return on equity has surged by 75% YoY and by 23% QoQ

The ROS has plunged by 67% YoY and by 19% from the previous quarter

The ROA has soared by 66% YoY and by 20% from the previous quarter

What is HTBX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for HTBX.

How did Heat Biologics financials performed over time

The quick ratio has grown by 42% from the previous quarter

The current ratio is up by 41% since the previous quarter

The debt is 99% smaller than the equity

The debt to equity has dropped by 88% year-on-year and by 50% since the previous quarter

Heat Biologics's equity has increased by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.